Xlife Sciences AG: The project company FUSE-AI GmbH reaches another milestone by developing ProstateCarcinoma.ai
The team at FUSE-AI (a project company of Xlife Sciences AG) has been working vigorously on the development of the software ProstateCarcinoma.ai. The recently completed demonstrator proves that the partial aspects relevant for prostate cancer diagnosis in prostate recognition and lesion detection are possible. This newly developed product offers both medical and economic advantages for future users. These advantages are prerequisites for future certification and commercialisation as a medical device.
The backbone of this new development is AI, it was also the first part finalized by the team at FUSE-AI. This is an infrastructure for the reproducible and scalable execution of deep learning experiments and for the generation of AI modules. Based on an initial set of training data, all central AI modules were created using the AI backbone. FUSE-AI achieves very high diagnostic integrity for prostate segmentation. This is also a prerequisite for a medical device to be approved.
In order to increase the accuracy of lesion detection in the next development phase, the project company has established collaborations with various clinics and they have also obtained grants. This ensures an increase in the amount of training data and quality and opens up the possibility for the clinical validation of ProstateCarcinoma.ai.
About FUSE-AI GmbH
About Xlife Sciences AG
Xlife Sciences AG (m:access: XLS) is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.
End of Media Release
Issuer: Xlife Sciences AG
Key word(s): Research/Technology
10.06.2020 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
|Company:||Xlife Sciences AG|
|Phone:||0041 44 385 84 60|
|Listed:||Regulated Unofficial Market in Munich|
|EQS News ID:||1066037|
|End of News||DGAP Media|